30 results about "PINK1" patented technology

The invention discloses a Parkinson's disease gene diagnosis kit which comprises 11 pathogenic genes of the Parkinson's disease namely SNCA,Parkin,Pink1,UCHL-1,DJ-1,ATP13A2,GIGYF2,HTRA2,FBX07,Vps35 and MAPT. A detection method comprises the following steps: designing and synthesizing specific primers of all genes, collecting specimens of individuals to be detected, sequencing specific DNA fragments obtained by all genes through a RT-PCR technology, comparing the gene sequence with a normal gene sequence, and analyzing whether deleterious mutations exit or not to evaluate disease risks of the individuals. By adopting the Parkinson's disease gene diagnosis kit disclosed by the invention, different deleterious mutations of a pathogenic gene protein coding region (CDS) can be detected at a time, the method is simple, convenient and rapid, the specificity is good, the sensitivity is high and the Parkinson's disease gene diagnosis kit can be used for pathogenic gene screening and early diagnosis of the Parkinson's disease.

The invention provides a method for rapidly establishing an animal model of Parkinson's disease through substantia nigra gene knockout. The invention discloses sgRNA capable of efficiently specifically knocking out PINK1 genes, and further provides a method for establishing the animal model of Parkinson's disease by virtue of targeted knockout of PINK1 genes in substantia nigra of animals. The method specifically comprises the following steps: injecting sgRNA and CRISPR nuclease into a substantia nigra part of the animal brain, and causing target fragment deletion to the PINK1 genes. Obvious typical dyskinesia symptoms of Parkinson's disease can occur within 3-4 weeks, and the dyskinesia cannot restore without drug therapy. The method directly causes neuronal death of the substantia nigrapart, does not have any side effect, has the mold establishment success rate of 90% or higher, has phenotypic stability and excellent applicability and repeatability, provides important models for screening drugs for the Parkinson's disease, performing stem cell treatment and gene defect repair treatment, researching pathogenesis of deletion of the PINK1 genes and the like, and has huge economic value and preclinical study significances.

The present disclosure relates generally to compositions and methods for treating, preventing, inhibiting, or delaying central nervous system degeneration. The disclosure relates to a recombinant genetherapy vector comprising a PARK2, PINK1, DJ-1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA gene, or functional fragment or variant thereof. The disclosure also relates to CRISPR / Cas-based gene editing systems for treating, preventing, inhibiting, or delaying central nervous system degeneration.

The invention provides application of UFP-512 to mitochondria protection and autophagy induction, and provides application of the UFP-512 to preparing medicines for preventing or delaying or treatingsymptoms related to and affected by mitochondria. It is shown through experimental data that the UFP-512 can effectively improve the mitochondrial membrane potential depolarization, increase the mitochondria ATP yield and reduce the cellular oxidation stress. Meanwhile, the UFP-512 can induce the autophagy of the mitochondria depending on PINK1-Parkin, thereby further clearing away the damaged mitochondria and keeping the environment in the mitochondria stable, and the application gap of diseases related to mitochondria damage and mitochondria autophagy difficulty is made up through the targeted protection effect of the UFP-512 on the mitochondria and the induction effect of the UFP-512 on the autophagy of the mitochondria.

The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses.

The invention provides a method for rapidly establishing an animal model of Parkinson's disease through substantia nigra gene knockout. The invention discloses sgRNA capable of efficiently specifically knocking out PINK1 genes, and further provides a method for establishing the animal model of Parkinson's disease by virtue of targeted knockout of PINK1 genes in substantia nigra of animals. The method specifically comprises the following steps: injecting sgRNA and CRISPR nuclease into a substantia nigra part of the animal brain, and causing target fragment deletion to the PINK1 genes. Obvious typical dyskinesia symptoms of Parkinson's disease can occur within 3-4 weeks, and the dyskinesia cannot restore without drug therapy. The method directly causes neuronal death of the substantia nigrapart, does not have any side effect, has the mold establishment success rate of 90% or higher, has phenotypic stability and excellent applicability and repeatability, provides important models for screening drugs for the Parkinson's disease, performing stem cell treatment and gene defect repair treatment, researching pathogenesis of deletion of the PINK1 genes and the like, and has huge economic value and preclinical study significances.

The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. ThePINK1-CTD polypeptide inhibits, prevents and / or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressingcancer therapy.

The invention discloses a protective agent for mitochondrial function of weaned piglets, which comprises the following components: 0.3-1.5 parts by weight of ellagic acid, 0.3-2 parts by weight of curcumin, 0.3-1.3 parts by weight of syringin, and 3-3 parts by weight of sodium montmorillonite 15 parts by weight. Compared with the single addition of ellagic acid, curcumin, syringin and sodium montmorillonite in the feed, the protective agent for mitochondrial function of weaned piglets of the present invention significantly improves the content of mitochondrial DNA in the intestinal tract and liver of post-weaned piglets, and the mitochondrial respiratory chain. Complex IV activity, expression of mitophagy marker proteins PINK1, Parkin, and LC3II / LC3I. Ellagic acid, curcumin, syringin, and sodium montmorillonite have significant interactions in improving intestinal and liver mitochondrial function and mitophagy levels, and have a positive synergistic combination effect. The protective agent for mitochondrial function of weaned piglets of the present invention can significantly improve the mitochondrial autophagy levels of the intestinal tract and liver after weaning through the synergistic effect of various components, and greatly improve the mitochondrial functions of the intestinal tract and liver after weaning.

The invention discloses a mitophagy regulator for relieving pig oxidative stress, which comprises the following components: 6-13 parts by weight of butyrate, 1-3 parts by weight of Achyranthes knuckle polysaccharide, 5-10 parts by weight of betaine, sodium-based 30-60 parts by weight of montmorillonite. Compared with the addition of butyrate, achyranthes bidentata polysaccharide, betaine and sodium montmorillonite alone in the feed, the present invention can significantly reduce the production of reactive oxygen species in the mitochondria of the liver and intestinal tract and the content of peroxidation product malondialdehyde, and promote oxidation stress. The expression of mitophagy marker proteins PINK1, Parkin, and LC3II / LC3I in pig liver and intestine after stimulation significantly increased the content of mitochondrial DNA and the activity of mitochondrial oxidative respiratory chain complex IV in pig liver and intestine. Moreover, Na-based montmorillonite has a controlled-release effect on butyrate, Achyranthes bidentata polysaccharide, and betaine, making it easy to mix with feed, forming a uniform dispersion system, and easy to use. Through the synergistic effect of each component, the invention significantly improves the level of pig mitophagy, protects the function of mitochondria, and then significantly relieves the oxidative stress of pigs.

The invention discloses application of a target drug in resisting atherosclerosis. The application comprises the following steps of: taking a mitochondrial autophagy signal channel mediated by nobiletin PINK1 / Parkin as a drug target; and / or taking an NLRP3 inflammasome signal channel as a drug target. According to the invention, with the application of the nobiletin, the blood fat level of atherosclerosis can be significantly reduced; the plaque structure can be significantly improved; the plaque stability can be improved; the inflammatory reaction can be inhibited; the nobiletin uses the mitochondrial autophagy signal channel mediated by the PINK1 / Parkin as the drug target; and / or, the NLRP3 inflammasome signal channel is used as the drug target; the nobiletin can be used as the effective tool for stabilizing the arteriosclerosis plaque, and provides the foundation for the development of the arteriosclerosis prevention and treatment drug; and in addition, the nobiletin is derived from the natural plant, has characteristics of wide source, low toxic-side effect, and anti-atherosclerosis effect, and has great market prospects and economic values.

The present invention discloses a polypeptide for preparing anti-PINK1 polyclonal antiserum and application thereof. The polypeptide of the invention is one polypeptide selected from a) and b): a) the polypeptide which is composed of amino acid sequence shown by the sequence 2 in a sequence table; and b) the polypeptide which is derived from the amino acid sequence of sequence 2 in the sequence table through substitution and / or absence and / or adding one or a plurality of amino acids. The invention also discloses the DNA molecule encoding the polypeptide. The anti-PINK1 polyclonal antiserum prepared according to the invention not only can be used for detecting Western blot, but also can be applied to immunohistochemical analysis. The anti-PINK1 polyclonal antiserum prepared according to the invention is of great significance in diagnosing and treating the disease related with PD and PINK1.

The invention relates to the field of gene engineering, in particular to a target protein of Parkinson's disease (PD) and an encoding gene and application thereof, and particularly relates to preparation of a gene targeting drug aiming at the key gene. The target protein finds that a target gene ZIP13 and Transferrin (Tsf) for Parkinson's disease are provided, and the PD condition is remarkably relieved or delayed by over-expressing the ZIP13 or interfering the Tsf through gene silencing. According to the target protein the human PD target protein comprises amino acid sequences represented bySEQ ID No. 5 and SEQ ID No. 6, and the gene comprises nucleotide sequences represented by SEQ ID No. 7 and SEQ ID No. 8. According to the target gene, an RNAi vector carrying a target gene is constructed, and the athletic ability of a PD patient can be improved through gene silencing or gene overexpression, and PD symptoms caused by knockdown of PINK1 is relieved or prevented. The target protein is expected to provide a novel treatment strategy and a key target for treating hereditary PD.

The invention relates to a human serine / threonine kinase PINK1 mutant protein and application thereof. A plurality of patients suffering from leukemia and parkinson's disease are used as studying cases, gene detection and analysis on the cases are performed, the human serine / threonine kinase PINK1 mutant protein is determined, a gene chip, a monoclonal antibody and an ELISA kit are prepared according to the human serine / threonine kinase PINK1 mutant protein, a guidance function is provided for gene diagnosis of patients suffering from leukemia and parkinson's disease, and a scientific basis isprovided for diagnosis and treatment of leukemia and parkinson's disease.

A diagnosis chip of recessive pathogenic genetic genes of a Parkinson disease has 96 mutational site sequences, namely 23 Parkin, 19 PINK1, 6 DJ-1, 14 ATP13A2, 25 PLA2G6 and 9 FBXO7. The chip comprises the following test steps of: fabricating an SUD plate, resuspending the SUD plate, fabricating an ASE plate, adding MEL, performing preliminary work on PCR (Polymerase Chain Reaction), combining PCR products, preparing a pre-chip sample, performing chip hybridization, cleaning and scanning the chip, and reading and analyzing data. The diagnosis chip of the recessive pathogenic genetic genes of the Parkinson disease is low in cost, and can screen the recessive pathogenic genetic genes of the Parkinson disease conveniently and rapidly.

The present invention relates to the field of genetic engineering, in particular, the present invention relates to a target protein of Parkinson's Disease (PD) and its encoding gene and application, and particularly relates to the preparation of gene-targeted drugs for the above-mentioned key genes. The present invention provides the target genes ZIP13 and Transferrin (Tsf) of Parkinson's disease, and significantly alleviates or delays PD by overexpressing ZIP13 or interfering with Tsf by gene silencing. According to the present invention, the target protein of human PD includes the amino acid sequences shown in SEQ ID No. 5 and SEQ ID No. 6, and the gene includes the nucleus as shown in SEQ ID No. 7 and SEQ ID No. 8. nucleotide sequence. According to the target gene of the present invention, constructing an RNAi vector carrying the target gene can be used to improve the exercise ability of PD patients through gene silencing or gene overexpression, and slow down or prevent PD symptoms caused by knockdown of PINK1. This invention is expected to provide new therapeutic strategies and key targets for the treatment of hereditary PD.

The invention discloses a Parkinson's disease gene diagnosis kit which comprises 11 pathogenic genes of the Parkinson's disease namely SNCA,Parkin,Pink1,UCHL-1,DJ-1,ATP13A2,GIGYF2,HTRA2,FBX07,Vps35 and MAPT. A detection method comprises the following steps: designing and synthesizing specific primers of all genes, collecting specimens of individuals to be detected, sequencing specific DNA fragments obtained by all genes through a RT-PCR technology, comparing the gene sequence with a normal gene sequence, and analyzing whether deleterious mutations exit or not to evaluate disease risks of the individuals. By adopting the Parkinson's disease gene diagnosis kit disclosed by the invention, different deleterious mutations of a pathogenic gene protein coding region (CDS) can be detected at a time, the method is simple, convenient and rapid, the specificity is good, the sensitivity is high and the Parkinson's disease gene diagnosis kit can be used for pathogenic gene screening and early diagnosis of the Parkinson's disease.